TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24964084
Drug: EV71-C4a vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71-C4a vaccine
Study: 24964817
Drug: Initial altered
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial altered cardiac metabolism
Study: 24965748
Drug: Orteronel 300
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orteronel 300 mg twice daily until PSA progression, metastases, or unacceptable toxicity.
Study: 24965999
Drug: Unilateral laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral laparoscopic ovarian drilling with thermal doses adjusted to ovarian volume: median of 720J (IQR)
Study: 24965999
Drug: Bilateral drilling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral drilling with fixed doses of 1200J
Study: 24966411
Drug: Phytase added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytase added to maize porridge immediately before consumption or used for dephytinization during meal preparation
Study: 24969506
Drug: Aspirin within
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin within 24 hours
Study: 24969516
Drug: Doxycycline monohydrate,
Normalized name: Doxycycline Monohydrate, monohydrate 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline monohydrate, 50 mg/d for 24 months
Study: 24969797
Drug: Postoperative hyperfractionated
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative hyperfractionated radiation therapy (36 Gy to craniospinal axis, 68 Gy to tumor region, 72 Gy to residual tumor, fractionated at 2 × 1 Gy per day 5 days per week) followed by maintenance chemotherapy (lomustine, cisplatin, and vincristine)
Study: 24969797
Drug: Postoperative hyperfractionated
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative hyperfractionated radiation therapy followed by maintenance chemotherapy
Study: 24970468
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H)
Study: 24970686
Drug: 3% saline
Normalized name: dextrose 2.5%-0.3% saline (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% saline infusion
Study: 24970773
Drug: Escitalopram, sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, sertraline, or extended-release venlafaxine (8-week course)
Study: 24972362
Drug: Tranylcypromine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine up to 60 mg/d
Study: 24972362
Drug: Tranylcypromine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine up to 120 mg/d
Study: 24974232
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of loop diuretics (furosemide)
Study: 24974232
Drug: Bolus treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus treatment of loop diuretics (furosemide)
Study: 24975800
Drug: Mannitol bronchial
Normalized name: MANNITOL BRONCHIAL CHALLENGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol bronchial challenge (PD15 < 635 mg)
Study: 24975800
Drug: Methacholine bronchial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine bronchial challenge (PC20 < 16 mg/mL)
Study: 24975800
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between log-transformed mannitol and methacholine response-dose ratios
Study: 24975809
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg daily for a mean of 10.0 days (range: 2.0 to 39.0 days)
Study: 24975809
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg daily
Study: 24976801
Drug: Community psychiatry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community psychiatry program (including psychiatrist appointments, individual and group therapy, enhanced access to psychiatric medications) for 1 year
Study: 24977639
Drug: Simulated effect-site
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated effect-site target of 3.2 μg/mL
Study: 24978858
Drug: Oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic drugs (OAD)
Study: 24979126
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available medical therapies (non-ESDS group)
Study: 24980704
Drug: WHO criteria
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO criteria for GDM (fasting plasma glucose ≥ 7.0 mmol/L and/or 2-hour plasma glucose ≥ 7.8 mmol/L)
Study: 24980704
Drug: Simplified IADPSG
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified IADPSG criteria (fasting glucose ≥ 5.1 mmol/L and/or 2-h plasma glucose ≥ 8.5 mmol/L)
Study: 24982681
Drug: Transdermal 17β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β estradiol (TBE)
Study: 24982681
Drug: Oral 17β
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17β estradiol (OBE)
Study: 24982681
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (OCEE)
Study: 24983206
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of initial antibiotic treatment
Study: 24986638
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment for 14 weeks
Study: 24988120
Drug: NT-proBNP ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP ≥ 160 pg/mL
Study: 24988120
Drug: Both TRV
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL
Study: 24988476
Drug: Metformin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (oral medication)
Study: 24990396
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg bid maintenance dose (MD)
Study: 24990396
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg bid MD
Study: 24990578
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with treatment interruption
Study: 24990911
Drug: Influenza A(H1N1)
Normalized name: influenza A(H1N1)vac mv-sp2009 15 mcg/0.5 mL INTRAMUSC VIAL (ML)
DrugBank: Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) (DB14444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A(H1N1) vaccine
Study: 24991041
Drug: 1 mg/d
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/d of folic acid (Pregnant Women)
Study: 24991041
Drug: 0 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/d of folic acid (Nonpregnant Women - NPW-0)
Study: 24991041
Drug: 1 mg/d
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/d of folic acid (Nonpregnant Women - NPW-1)
Study: 24991041
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d of folic acid (Nonpregnant Women - NPW-5)
Study: 24992294
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg once daily with tenofovir
Study: 24992294
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg once daily without tenofovir
Study: 24992948
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 0.75 g L-alanine-L-glutamine for 24 hours
Study: 24992948
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 0.75 g L-alanine-L-glutamine for 5 days
Study: 24996961
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification intervention; details on dosage and duration not available.
Study: 24997153
Drug: Deferasirox at
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox at a starting dose of 10 mg/kg/day for 52 weeks
Study: 24997153
Drug: Deferasirox therapy
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox therapy continued
Study: 24997153
Drug: Deferasirox therapy
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox therapy discontinued
Study: 24997880
Drug: Oral cysteamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cysteamine bitartrate (60 mg/kg per day) and N-acetylcysteine (60 mg/kg per day)
Study: 24997880
Drug: Oral cysteamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cysteamine bitartrate and N-acetylcysteine
Study: 25001321
Drug: ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranibizumab (0.5 mg)
Study: 25001321
Drug: bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: bevacizumab (1.25 mg)
Study: 25001321
Drug: aflibercept (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: aflibercept (2.0 mg)
Study: 25001524
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m² i.v. Q3W plus oral prednisone/prednisolone 10 mg daily
Study: 25002028
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CDK 4/6 inhibitors and PI3K inhibitors
Study: 25002028
Drug: Single-agent PI3K
Normalized name: Pi3k.delta.-in-2
DrugBank: Linperlisib (DB17235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent PI3K inhibitors
Study: 25002028
Drug: PI3K inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI3K inhibitor BYL719
Study: 25002028
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PI3K and CDK 4/6 inhibitors
Study: 25003311
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery system; subjects received three mixed meals (1 g of carbohydrate/kg of body weight; 100 g maximum) with meal announcement and automated insulin dosing.
Study: 25003359
Drug: Fingolimod (FTY720,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (FTY720, Gilenya), 0.5 mg, orally for 3 consecutive days
Study: 25005255
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab with chemotherapy
Study: 25005444
Drug: Desmopressin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.4 μg/kg IV
Study: 25007130
Drug: AZD8931 ([(14)C]-AZD8931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 ([(14)C]-AZD8931) administered orally or intravenously; dosage not specified; single doses.
Study: 25007130
Drug: AZD8931 metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 metabolism in rats; specific metabolic pathways not detailed.
Study: 25007130
Drug: AZD8931 metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 metabolism in dogs; specific metabolic pathways not detailed.
Study: 25007130
Drug: AZD8931 metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 metabolism in humans; specific metabolic pathways not detailed.
Study: 25007944
Drug: Imatinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 200 mg/day for 6 months
Study: 25008856
Drug: Provided diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided diet containing 6-cup equivalents (1046 g/d) of vegetables and fruit (8 wk, phase 2)
Study: 25008917
Drug: HIV-1 gp140
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 gp140 linked to HSP70 administered vaginally
Study: 25009010
Drug: AKT inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT inhibitor treatment during the fourth line of therapy
Study: 25009013
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with cetuximab, paclitaxel, and carboplatin
Study: 25009013
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with cetuximab, paclitaxel, and carboplatin followed by CRT
Study: 25009371
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with albumin dialysis
Study: 25010745
Drug: Magnesium at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium at 2.5 mmol/l
Study: 25010745
Drug: Magnesium at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium at 1 mmol/l
Study: 25011615
Drug: Epoetin zeta
Normalized name: Epoetin zeta
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin zeta (median dose 30,000 IU/week)
Study: 25011656
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg linezolid intravenously twice a day
Study: 25012994
Drug: Birth control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth control pill users (females)
Study: 25012994
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy users (females)
Study: 25015089
Drug: Capecitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1250 mg/m²) single-dose 2-3 hours before surgery
Study: 25015089
Drug: Lapatinib (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1250 mg) daily for 2-5 doses, last dose 2-3 hours before surgery
Study: 25015202
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation with weekly paclitaxel (60 mg/m² administered once weekly for 5 weeks during radiation therapy)
Study: 25015413
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g oral glucose tolerance test (OGTT) using IADPSG criteria
Study: 25015413
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose challenge test (GCT)
Study: 25015413
Drug: Standardized routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized routine care protocol for diabetes and GDM treatment
Study: 25016003
Drug: Imexon (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imexon (1000 mg/m² IV daily for 5 days in 21-day cycles)
Study: 25016127
Drug: Intravenous hematin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hematin
Study: 25016368
Drug: Obstructive Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstructive Sleep Apnea (OSA) treatment according to national guidelines
Study: 25016924
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg intravenously every 2 weeks)
Study: 25018910
Drug: Bone marrow-derived,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived, culture-expanded allogeneic mesenchymal stem cells administered into the suprarenal aorta after reflow.
Study: 25019562
Drug: T1 time
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1 time 12 minutes after contrast material injection
Study: 25019562
Drug: T1 time
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1 time 25 minutes after contrast material injection
Study: 25020262
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite in a continual infusion of 750μg/24h for 6 days
Study: 25022285
Drug: Rosuvastatin 5-20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5-20 mg/day
Study: 25022828
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg (Clop-75)
Study: 25022828
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg (Pras-5)
Study: 25022828
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg (Pras-10)
Study: 25022935
Drug: Omentin-1 levels
Normalized name: benztropine mesylate 1 MG/ML [Cogentin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omentin-1 levels in AMI patients at baseline: 18.73 ± 3.66 ng/ml
Study: 25022935
Drug: Chemerin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemerin levels in AMI patients at baseline: 263.37 ± 73.32 ng/ml
Study: 25023888
Drug: Liraglutide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (50 μg/kg; i.p.)
Study: 25023888
Drug: Imipramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (10 mg/kg; i.p.)
Study: 25023888
Drug: Liraglutide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (50 μg/kg; i.p., daily for 3 weeks)
Study: 25023888
Drug: Olanzapine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (0.5 mg/kg; p.o. for 8-9 weeks)
Study: 25023926
Drug: Time controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time controls (no diet therapy)
Study: 25024303
Drug: DA-EPOCH-R (infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EPOCH-R (infusional dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine, prednisone, and rituximab)
Study: 25025963
Drug: Olaparib (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (up to 400 mg bid) plus liposomal doxorubicin (PLD) 40 mg m(-2)
Study: 25025963
Drug: Olaparib (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (up to 400 mg bid) plus PLD 40 mg m(-2)
Study: 25028353
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (serum 25OHD < 50 nmol/L)
Study: 25028353
Drug: Sufficient Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient Vitamin D (serum 25OHD ≥ 50 nmol/L)
Study: 25029335
Drug: JAK inhibitors
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitors on lymphocytes from affected children
Study: 25030840
Drug: Oral QLT091001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral QLT091001 (10-40 mg/m(2) per day for 7 days)
Study: 25032816
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment for 12 weeks
Study: 25034977
Drug: plm60-s at
Normalized name: crospovidone (15 mpa.s at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: plm60-s at 10 mg/m(2)
Study: 25034977
Drug: plm60-s at
Normalized name: crospovidone (15 mpa.s at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: plm60-s at 18 mg/m(2)
Study: 25034977
Drug: c-MI at
Approvals — FDA: no, EMA: no, PMDA: no
Description: c-MI at 10 mg/m(2)
Study: 25037041
Drug: Maternal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal vitamin D insufficiency (<32 ng/mL)
Study: 25037684
Drug: IV trebananib
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV trebananib 15 mg/kg QW plus paclitaxel 175 mg/m(2) Q3W and carboplatin 6 mg/mL · min Q3W followed by trebananib 15 mg/kg QW monotherapy for 18 months
Study: 25037863
Drug: Continuous daily
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous daily oral afatinib (30 mg starting dose, escalation to 50 mg) combined with intravenous pemetrexed (500 mg/m2)
Study: 25037863
Drug: Pulsed-dose daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-dose daily oral afatinib (50 mg starting dose, escalation to 70 mg) combined with intravenous pemetrexed (500 mg/m2)
Study: 25037863
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing schedules (SA and SB)
Study: 25038354
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg and weight-based ribavirin for 12 weeks
Study: 25038354
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg and weight-based ribavirin for 24 weeks
Study: 25038354
Drug: Sofosbuvir and
Normalized name: sofosbuvir and ledipasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir and ribavirin treatment
Study: 25038824
Drug: Cetuximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (500 mg/m2, 2 h) + Irinotecan (125 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Study: 25038824
Drug: Cetuximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (500 mg/m2, 2 h) + Irinotecan (165 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Study: 25038824
Drug: Cetuximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (500 mg/m2, 2 h) + Irinotecan (95 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Study: 25040144
Drug: Serum 1,3-beta-d-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 1,3-beta-d-glucan (BDG) testing prior to initiation of antifungal (AF) treatment
Study: 25040462
Drug: venlafaxine 150
Normalized name: venlafaxine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine 150 mg/day for 6 weeks
Study: 25042202
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg per day plus R-CHOP
Study: 25042797
Drug: Peginterferon lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda-1a (Lambda) at 120, 180, and 240 μg with ribavirin
Study: 25042797
Drug: Peginterferon lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda-1a (Lambda) at 240 μg with ribavirin